ROCKVILLE, Md.–Prolias, a biotechnology company using proprietary Bead BlotTM technology to develop ligand-based affinity resins that purify and target proteins and protein complexes, today announced that it has launched its first family of ProSpectrum LigandsTM. These ligands are focused on cardiovascular disease, with ligands that bind High-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), and cardiac Troponin I proteins.

The proprietary ProSpectrum LigandsTM utilize chemically synthesized peptide ligands on microscopic chromatography resin. Synthesis protocols enable controlled synthesis of identical peptide ligands, thereby increasing reproducibility performance. Chemical peptide ligands rival antibodies for selectivity and specificity, with lower cost and more reproducible production.

ProSpectrum LigandsTM provide a robust matrix that allows scientists and researchers to bind, and purify, specifically targeted proteins and physiological protein complexes from complex biological sources, including whole blood, plasma and serum.

About Prolias

Prolias, is a privately held biotechnology company dedicated to the discovery and development of novel therapeutic proteins using proprietary FIoNATM and Bead BlotTM technologies. Prolias is developing ligand based affinity resins to purify proteins quickly from a variety of biological samples, including, whole blood. Additional information is available at www.proliastechnologies.com

This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Prolias’ mission. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Prolias cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to: Prolias’ expectations that they will incur operating losses in the near future, the early stage of preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, the actions of competitors and the development of competing technologies, potential patent infringement claims against Prolias’ products, processes and technologies, Prolias’ ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.